Francois Brisebois
Stock Analyst at Oppenheimer
(1.77)
# 3,348
Out of 5,090 analysts
88
Total ratings
38.64%
Success rate
-0.7%
Average return
Main Sectors:
Stocks Rated by Francois Brisebois
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AQST Aquestive Therapeutics | Maintains: Outperform | $7 → $8 | $6.38 | +25.39% | 3 | Sep 8, 2025 | |
| SVRA Savara | Maintains: Outperform | $5 → $6 | $6.50 | -7.69% | 6 | Aug 15, 2025 | |
| SNSE Sensei Biotherapeutics | Maintains: Outperform | $70 → $80 | $9.72 | +723.05% | 2 | Mar 28, 2025 | |
| ABEO Abeona Therapeutics | Initiates: Outperform | $16 | $4.88 | +228.21% | 1 | Mar 5, 2025 | |
| OVID Ovid Therapeutics | Upgrades: Outperform | $4 | $1.67 | +139.52% | 1 | Jan 29, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Outperform | $65 → $72 | $81.77 | -11.95% | 7 | Jan 22, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Outperform | $59 → $61 | $39.83 | +53.15% | 6 | Jan 13, 2025 | |
| MNMD Mind Medicine (MindMed) | Reiterates: Outperform | $20 | $12.35 | +61.94% | 4 | Dec 17, 2024 | |
| TRDA Entrada Therapeutics | Maintains: Outperform | $25 → $28 | $10.34 | +170.79% | 2 | Nov 6, 2024 | |
| AVDL Avadel Pharmaceuticals | Maintains: Outperform | $29 → $30 | $21.34 | +40.58% | 8 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $143 → $163 | $247.99 | -34.27% | 4 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $55 | $20.28 | +171.20% | 5 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $15 | $0.90 | +1,566.67% | 2 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $6 | $8.78 | -31.66% | 5 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $4.62 | +138.10% | 6 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $29.91 | -53.19% | 2 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $4.26 | +486.85% | 1 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $55 → $65 | $19.64 | +230.96% | 5 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $4.70 | +112.77% | 2 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $152 | $5.99 | +2,437.56% | 2 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $36 | $17.68 | +103.62% | 4 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $100 → $60 | $0.28 | +21,482.73% | 3 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7,200 → $5,400 | $1.68 | +321,328.57% | 2 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $11 | $3.08 | +257.14% | 2 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $18 | $3.60 | +400.00% | 1 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $5.82 | +759.11% | 1 | Oct 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $3,240 | $1.12 | +289,185.71% | 1 | Feb 4, 2020 |
Aquestive Therapeutics
Sep 8, 2025
Maintains: Outperform
Price Target: $7 → $8
Current: $6.38
Upside: +25.39%
Savara
Aug 15, 2025
Maintains: Outperform
Price Target: $5 → $6
Current: $6.50
Upside: -7.69%
Sensei Biotherapeutics
Mar 28, 2025
Maintains: Outperform
Price Target: $70 → $80
Current: $9.72
Upside: +723.05%
Abeona Therapeutics
Mar 5, 2025
Initiates: Outperform
Price Target: $16
Current: $4.88
Upside: +228.21%
Ovid Therapeutics
Jan 29, 2025
Upgrades: Outperform
Price Target: $4
Current: $1.67
Upside: +139.52%
Tarsus Pharmaceuticals
Jan 22, 2025
Maintains: Outperform
Price Target: $65 → $72
Current: $81.77
Upside: -11.95%
Harmony Biosciences Holdings
Jan 13, 2025
Maintains: Outperform
Price Target: $59 → $61
Current: $39.83
Upside: +53.15%
Mind Medicine (MindMed)
Dec 17, 2024
Reiterates: Outperform
Price Target: $20
Current: $12.35
Upside: +61.94%
Entrada Therapeutics
Nov 6, 2024
Maintains: Outperform
Price Target: $25 → $28
Current: $10.34
Upside: +170.79%
Avadel Pharmaceuticals
Oct 31, 2024
Maintains: Outperform
Price Target: $29 → $30
Current: $21.34
Upside: +40.58%
Oct 31, 2024
Maintains: Outperform
Price Target: $143 → $163
Current: $247.99
Upside: -34.27%
Sep 3, 2024
Reiterates: Outperform
Price Target: $55
Current: $20.28
Upside: +171.20%
Aug 19, 2024
Reiterates: Outperform
Price Target: $15
Current: $0.90
Upside: +1,566.67%
Aug 16, 2024
Reiterates: Outperform
Price Target: $6
Current: $8.78
Upside: -31.66%
Aug 15, 2024
Reiterates: Outperform
Price Target: $11
Current: $4.62
Upside: +138.10%
Aug 14, 2024
Reiterates: Outperform
Price Target: $14
Current: $29.91
Upside: -53.19%
Jun 25, 2024
Initiates: Outperform
Price Target: $25
Current: $4.26
Upside: +486.85%
Jun 13, 2024
Maintains: Outperform
Price Target: $55 → $65
Current: $19.64
Upside: +230.96%
May 6, 2024
Reiterates: Outperform
Price Target: $10
Current: $4.70
Upside: +112.77%
Aug 30, 2023
Reiterates: Outperform
Price Target: $152
Current: $5.99
Upside: +2,437.56%
Aug 17, 2023
Maintains: Outperform
Price Target: $63 → $36
Current: $17.68
Upside: +103.62%
Apr 3, 2023
Maintains: Outperform
Price Target: $100 → $60
Current: $0.28
Upside: +21,482.73%
Feb 6, 2023
Maintains: Outperform
Price Target: $7,200 → $5,400
Current: $1.68
Upside: +321,328.57%
Aug 29, 2022
Maintains: Outperform
Price Target: $17 → $11
Current: $3.08
Upside: +257.14%
Jul 18, 2022
Assumes: Outperform
Price Target: $18
Current: $3.60
Upside: +400.00%
Oct 29, 2021
Initiates: Outperform
Price Target: $50
Current: $5.82
Upside: +759.11%
Feb 4, 2020
Initiates: Buy
Price Target: $3,240
Current: $1.12
Upside: +289,185.71%